Ocugen Stock News and Analysis: OCGN distributed COVID-19 vaccine approved by WHO
Premium|Take advantage of 50% OFF on your first month.
Start your subscription and get access to all our original articles.
You have reached your limit of 5 free articles for this month.
Get Premium without limits for only $9.99 for the first month
Access all our articles, insights, and analysts.
UNLOCK OFFER- WHO meeting on Wednesday will determine whether Covaxin can receive Emergency Use Listing.
- Ocugen owns rights to distribute Bharat Biotech's COVID-19 vaccine in the US and Canada.
- OCGN stock rose 12.1% on Tuesday in anticipation.
Update after Wednesday close: Ocugen (OCGN) closed Wednesday down nearly 15% at $13.37 after another tumulotous session. the stock surged as high as $17.65 before sliding as the afternoon wore on. It appears to have been a case of buy the rumour sell the fact as the WHO confirmed its approval for Covaxin. This had been rumoured for some time and social media mentions of OCGN had been rising.
UPDATE: WHO approved the India-based Bharata Biotech's Covaxin vaccine for an Emergency Use Listing that will allow it to be purchased and donated to the COVAX facility that distributes vaccines worldwide through the Vaccine Alliance. Ocugen has the rights to distribute it in the US and Canada. The stock is down 5.7% at $14.77 in Wednesday's session.
Ocugen (OCGN) jumped 12.1% to close at $15.67 on Tuesday, just one day after it bounced by 18.1% to $13.98. The entirety of the OCGN price rise is anticipation for today, Wednesday, November 3, when the World Health Organization (WHO) is expected to have its final technical meeting concerning the efficacy of a COVID-19 vaccine designed by one of Ocugen's partners. The stock was down 4.8% on Wednesday's premarket at $14.92.
OCGN News: All about Covaxin
The day has come. A technical advisory panel from the WHO is slated to determine whether India-based Bharat Biotech's Covaxin vaccine has all the necessary data to be given an Emergency Use Listing (EUL). The EUL would allow Covaxin to be used in the COVAX Facility, which distributes COVID-19 vaccines to hundreds of nations.
If Covaxin is approved, it will greatly benefit Bharat, a private company, but will it benefit OCGN stock? Ocugen only owns the rights to distribute the vaccine in the US and Canada, and those nations are donors rather than beneficiaries of the COVAX Facility.
Of course, maybe the approval of the drug for a EUL signifies a greater likelihood that regulators in the US and Canada will approve Covaxin for their own citizens. The more significant future dates for OCGN shareholders are when Canada approves its application to distribute it there, and if or when the US Food & Drug Administration approves its phase-3 study. Both of those dates are uncertain, however, so the current market focus on the WHO is the only news to trade on.
Bharat Biotech submitted its forms for EUL listing on April 19. The first meeting with the WHO on October 26 ended with the organization asking Bharat to submit additional information and data. The Technical Advisory Group for Emergency Use Listing is actually an independent advisory commission organized under the aegis of the WHO.
OCGN key statistics
| Market Cap | $2.8 billion |
| Price/Earnings | N/A |
| Price/Sales | N/A |
| Price/Book | 20.2 |
| Enterprise Value | $2.2 billion |
| Gross Margin | N/A |
| Net Margin |
N/A |
| 52-week high | $18.77 |
| 52-week low | $0.27 |
| Short Interest | 28.7% |
| Average Wall Street Rating and Price Target | Hold $8.88 |
OCGN Stock Chart: A day of reckoning for traders
Just as we had predicted, the stock closed at resistance on Tuesday at $15.67. From Tuesday's piece: "At Monday’s closing price of $13.98, the clear target is $16.20. This was the swing high from May 3. That spike was much lower than the February 8 spike that went as high as $18.77. The closing prices on those days were quite close – $15.68 and $15.81. This area may also act as resistance as some traders decide to bail."
Ocugen is a stock that has trended down for years and has lost as much as 99% of its value since its IPO in 2014. It traded for pennies in 2020 but is up more than 600% this year.
The target for longs remains $16.20, the high on May 3. After that, the next line in the sand is $18.77. With the stock already down some 4% in the premarket on Wednesday, however, we think it likely is that many in the market have already decided to sell the news. If the stock is not able to break through the current resistance zone and $16.20, then it will likely trade down as far as the 9-day moving average at $10.76.
FXStreet View: The advice stays the same: sell the news. From Tuesday's article: "No matter which way the decision goes at the WHO advisory meeting on Wednesday, OCGN stock is likely to sell off as it has in the past." If you are holding on Wednesday, now is the time to book profits. This will then allow you to buy back in at a lower price before the decisions by US and Canadian regulators.
OCGN daily chart
- WHO meeting on Wednesday will determine whether Covaxin can receive Emergency Use Listing.
- Ocugen owns rights to distribute Bharat Biotech's COVID-19 vaccine in the US and Canada.
- OCGN stock rose 12.1% on Tuesday in anticipation.
Update after Wednesday close: Ocugen (OCGN) closed Wednesday down nearly 15% at $13.37 after another tumulotous session. the stock surged as high as $17.65 before sliding as the afternoon wore on. It appears to have been a case of buy the rumour sell the fact as the WHO confirmed its approval for Covaxin. This had been rumoured for some time and social media mentions of OCGN had been rising.
UPDATE: WHO approved the India-based Bharata Biotech's Covaxin vaccine for an Emergency Use Listing that will allow it to be purchased and donated to the COVAX facility that distributes vaccines worldwide through the Vaccine Alliance. Ocugen has the rights to distribute it in the US and Canada. The stock is down 5.7% at $14.77 in Wednesday's session.
Ocugen (OCGN) jumped 12.1% to close at $15.67 on Tuesday, just one day after it bounced by 18.1% to $13.98. The entirety of the OCGN price rise is anticipation for today, Wednesday, November 3, when the World Health Organization (WHO) is expected to have its final technical meeting concerning the efficacy of a COVID-19 vaccine designed by one of Ocugen's partners. The stock was down 4.8% on Wednesday's premarket at $14.92.
OCGN News: All about Covaxin
The day has come. A technical advisory panel from the WHO is slated to determine whether India-based Bharat Biotech's Covaxin vaccine has all the necessary data to be given an Emergency Use Listing (EUL). The EUL would allow Covaxin to be used in the COVAX Facility, which distributes COVID-19 vaccines to hundreds of nations.
If Covaxin is approved, it will greatly benefit Bharat, a private company, but will it benefit OCGN stock? Ocugen only owns the rights to distribute the vaccine in the US and Canada, and those nations are donors rather than beneficiaries of the COVAX Facility.
Of course, maybe the approval of the drug for a EUL signifies a greater likelihood that regulators in the US and Canada will approve Covaxin for their own citizens. The more significant future dates for OCGN shareholders are when Canada approves its application to distribute it there, and if or when the US Food & Drug Administration approves its phase-3 study. Both of those dates are uncertain, however, so the current market focus on the WHO is the only news to trade on.
Bharat Biotech submitted its forms for EUL listing on April 19. The first meeting with the WHO on October 26 ended with the organization asking Bharat to submit additional information and data. The Technical Advisory Group for Emergency Use Listing is actually an independent advisory commission organized under the aegis of the WHO.
OCGN key statistics
| Market Cap | $2.8 billion |
| Price/Earnings | N/A |
| Price/Sales | N/A |
| Price/Book | 20.2 |
| Enterprise Value | $2.2 billion |
| Gross Margin | N/A |
| Net Margin |
N/A |
| 52-week high | $18.77 |
| 52-week low | $0.27 |
| Short Interest | 28.7% |
| Average Wall Street Rating and Price Target | Hold $8.88 |
OCGN Stock Chart: A day of reckoning for traders
Just as we had predicted, the stock closed at resistance on Tuesday at $15.67. From Tuesday's piece: "At Monday’s closing price of $13.98, the clear target is $16.20. This was the swing high from May 3. That spike was much lower than the February 8 spike that went as high as $18.77. The closing prices on those days were quite close – $15.68 and $15.81. This area may also act as resistance as some traders decide to bail."
Ocugen is a stock that has trended down for years and has lost as much as 99% of its value since its IPO in 2014. It traded for pennies in 2020 but is up more than 600% this year.
The target for longs remains $16.20, the high on May 3. After that, the next line in the sand is $18.77. With the stock already down some 4% in the premarket on Wednesday, however, we think it likely is that many in the market have already decided to sell the news. If the stock is not able to break through the current resistance zone and $16.20, then it will likely trade down as far as the 9-day moving average at $10.76.
FXStreet View: The advice stays the same: sell the news. From Tuesday's article: "No matter which way the decision goes at the WHO advisory meeting on Wednesday, OCGN stock is likely to sell off as it has in the past." If you are holding on Wednesday, now is the time to book profits. This will then allow you to buy back in at a lower price before the decisions by US and Canadian regulators.
OCGN daily chart
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.